Sartaj Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sartaj Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $56.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sartaj Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $56.0K Trade | TransData Nexus

Sartaj Pharma Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $56.0K Total Trade · DGFT Verified

Sartaj Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $56.0K across 2 products in 1 therapeutic categories. Based on 18 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Carfilzomib ($32.9K), Lenvatinib ($23.1K), .

Sartaj Pharma Private Limited — Export Portfolio & Destination Treemap

Sartaj Pharma Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sartaj Pharma Private Limited? — Company Overview & Market Position

Sartaj Pharma Private Limited, established on February 7, 2022, is a private limited company headquartered in Delhi, India. The company is registered under the Corporate Identification Number (CIN) U51909DL2022PTC393423. Its authorized and paid-up capital stands at ₹100,000 each, reflecting a modest financial foundation. The company's registered office is located at 1702-1703/215, S/F, Bhagirath Palace, Chandni Chowk, Delhi, 110006.

Sartaj Pharma specializes in the wholesale and manufacturing of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has developed a strong reputation for providing exceptional products and services, catering to a diverse clientele ranging from small businesses to multinational corporations. Their commitment to excellence has enabled them to distribute products to wholesalers and dealers globally, earning the trust of partners across various industries.

What Does Sartaj Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Carfilzomib$32.9K 2

Product Portfolio — Top 2 by Export Value

Sartaj Pharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Carfilzomib	Advanced Oncology	$32.9K	7	2.7%	2
2	Lenvatinib	Advanced Oncology	$23.1K	11	1.1%	12

Sartaj Pharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $56.0K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sartaj Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sartaj Pharma Private Limited operates manufacturing facilities that produce a range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details regarding the locations and capacities of these facilities are not publicly disclosed, the company emphasizes its commitment to quality and innovation, ensuring that all products meet stringent international standards.

3Key Leadership

The leadership team at Sartaj Pharma Private Limited comprises three directors:

Mohd Arif: Director since February 7, 2022.
Mukhtar Ahmad: Director since February 7, 2022.
Junaid Alam: Director since February 7, 2022.

These individuals bring a wealth of experience and strategic vision to the company, driving its growth and operational success. Their leadership is instrumental in steering Sartaj Pharma towards its mission of advancing healthcare through innovation and high-quality pharmaceutical products.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sartaj Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sartaj Pharma Private Limited's export activities, as per TransData Nexus proprietary trade data, are primarily focused on the Advanced Oncology therapeutic category, with products like Carfilzomib and Lenvatinib. The company has engaged in 18 shipments totaling $56,000 USD, with Carfilzomib accounting for $33,000 USD and Lenvatinib for $23,000 USD. These figures indicate a concentrated portfolio, with the top two products representing 100% of the export value. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The company's focus on oncology products suggests potential interest in these regulated markets, but further information is needed to assess their market presence and regulatory standing in these regions.

2Emerging Markets

Sartaj Pharma Private Limited's export data indicates a focus on the Advanced Oncology therapeutic category, with products like Carfilzomib and Lenvatinib. While specific details regarding the company's presence in emerging markets such as Africa, Latin America, and Southeast Asia are not publicly available, the company's emphasis on oncology products suggests potential interest in these regions. The World Health Organization's prequalification program could facilitate access to these markets, but further information is needed to assess Sartaj Pharma's engagement and regulatory standing in these areas.

Sartaj Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Sartaj Pharma Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data indicates a focus on oncology products, which may require FDA approvals for the US market. However, without publicly accessible records, it is challenging to assess the company's regulatory standing with the FDA.

2WHO & EU GMP

Sartaj Pharma Private Limited's commitment to quality is evident through its ISO 9001:2015 certification. However, specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. These certifications are crucial for accessing international markets and ensuring product quality. The absence of publicly accessible records makes it difficult to assess the company's compliance with these international standards.

3CDSCO & Indian Regulatory

Sartaj Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sartaj Pharma Private Limited operates in the competitive pharmaceutical industry, focusing on oncology products such as Carfilzomib and Lenvatinib. While specific market share data and a detailed competitive analysis are not publicly available, the company's concentrated product portfolio indicates a niche focus within the oncology segment. To enhance its competitive position, Sartaj Pharma could consider diversifying its product offerings and expanding into additional therapeutic areas.

2Key Differentiators

Sartaj Pharma Private Limited's key differentiators include its specialization in oncology products, particularly in the Advanced Oncology category, and its commitment to quality, as evidenced by its ISO 9001:2015 certification. The company's focus on high-quality pharmaceutical formulations and its ability to cater to a diverse clientele are also notable strengths. However, the lack of publicly available information regarding regulatory approvals and certifications makes it challenging to fully assess the company's competitive advantages.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Sartaj Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sartaj Pharma Private Limited has demonstrated a track record in exporting pharmaceutical formulations, with 18 shipments totaling $56,000 USD. The company's focus on oncology products indicates a specialized approach to product development and export. However, the lack of publicly available information regarding manufacturing facilities, regulatory approvals, and certifications makes it challenging to fully assess the company's reliability and consistency as a supplier. Prospective partners should conduct thorough due diligence to ensure alignment with quality standards and regulatory requirements.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the FDA directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with the World Health Organization's Good Manufacturing Practice standards. This can be verified by checking the WHO's official website or contacting the organization.

Frequently Asked Questions — Sartaj Pharma Private Limited

How many pharmaceutical products does Sartaj Pharma Private Limited export from India?

Sartaj Pharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Carfilzomib ($32.9K), Lenvatinib ($23.1K). Total export value is $56.0K.

What is Sartaj Pharma Private Limited's total pharmaceutical export value?

Sartaj Pharma Private Limited's total pharmaceutical export value is $56.0K, based on 18 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sartaj Pharma Private Limited cover?

Sartaj Pharma Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Sartaj Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.